

Applicant: Erik Buntinx
Serial No.: 10/580,962
Filed: May 31, 2006
Page 7 of 8

REMARKS

Claims 110-142 are pending in the subject application. By this amendment, Claims 114 and 115 have been amended to correct the spelling of pipamperone. Applicant maintains that the amendments do not raise an issue of new matter. Entry of the amendments is respectfully requested.

Status of U.S. Patent Family Member

Applicant would also like to direct the Examiner to the Notice of Allowance dated August 10, 2010 in connection with patent family member U.S. Patent Application No. 10/725,965. The allowed claims are directed to pharmaceutical compositions comprising pipamperone and citalopram in specified dosage amounts.

Supplemental Information Disclosure Statement

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the reference that are listed on the attached form PTO/SB/08A.

This Supplemental Information Disclosure Statement (SIDS) is being filed pursuant to 37 C.F.R. §1.97(b)(4) before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114. Accordingly, no fee is deemed necessary in connection with the filing of this SIDS.

Applicant: Erik Buntinx
Serial No.: 10/580,962
Filed: May 31, 2006
Page 8 of 8

CONCLUSIONS


No fee is deemed necessary in connection with the filing of this Supplemental Amendment and Information Disclosure Statement. However, if any fee is required with this reply or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: August 12, 2010
New York, New York

By



Alan D. Miller
Reg. No. 42,889